Clinical trials: Neoplasms, Solid Tumor
Cancer
Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors
In this phase I study we will characterize the safety, tolerability, maximum tolerated dose and dose-limiting toxicity of weekly bolus topotecan when administered in combination with two different dosing schedules of carboplatin.
- Trial name
- NCT00193583
- Testing
- Topotecan, Carboplatin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- SCRI Development Innovations, LLC
Cancer, Tumors
Detection of Tumor DNA in Blood Samples From Cancer Patients
The aim of this study is to employ genomic detection methodologies to measure the relative amount of tumor nucleic acids in the blood of a cancer patient with diagnosed metastatic disease that is either commencing, currently…
- Trial name
- NCT02288754
- Testing
- Blood test
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Lexent Bio, Inc.
Refractory Solid Tumors, Lymphomas
A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval
This is a double-blind (vis-a-vis lenvatinib), randomized, placebo-controlled, three-treatment, three-way crossover study in healthy subjects. There are two phases in this study: Pre-Randomization and Randomization.
- Trial name
- NCT01525394
- Testing
- Lenvatinib, Moxifloxacin 400 mg
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Metastatic Tumor, Advanced Tumor
Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.
The success of anti-CTLA4 therapy has inaugurated a paradigm shift in oncology where drugs target the immune system rather than cancer cells in order to stimulate the anti-tumor immune response.
- Trial name
- ISI-JX (NCT02977156)
- Testing
- Pexa-Vec, Ipilimumab
- Where
- 5 sites in France
- Volunteers
- 22 people
- Sponsor
- Centre Leon Berard
Hematologic Malignancy, Solid Tumor
Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors.
The allogeneic TCR-enhanced Vδ2 T cell product is a novel genetically engineered cellular therapeutic. By engineering a specific BTN protein-binding moiety on its cell surface, this product harnesses the intrinsic tumoricidal…
- Trial name
- NCT07570563
- Testing
- Allogeneic TCR-enhanced Vδ2 T cell Injection, Cyclophosphamide injection, Fludarabine Injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chinese PLA General Hospital
Solid Tumor
Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors
Multicenter, single arm, non-randomized, prospective, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (BEN101) followed by IL-2 after a…
- Trial name
- NCT05831033
- Testing
- BEN101
- Where
- 3 sites in China
- Volunteers
- 16 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Solid Tumor, Adult
Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
Single center, single arm phase Ib trial to test the feasibility and safety of Tumor- Infiltrating Lymphocyte-Adoptive Cell Therapy (TIL-ACT) combined with low-dose irradiation in patients with advanced or metastatic solid…
- Trial name
- NCT03992326
- Testing
- TIL, Cyclophosphamide, Fludarabine
- Where
- Switzerland
- Volunteers
- 6 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Solid Tumor
IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers
A Phase I, Open-label, Fixed-Sequence Study to Evaluate the Effect of Multiple-dose Itraconazole or Rifampicin Capsules on the Single-dose PK Profiles of IMP4297 Capsules in Healthy Subjects
- Trial name
- NCT04584515
- Testing
- IMP4297 40 mg, IMP4297 100 mg
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Impact Therapeutics, Inc.
EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma
A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies
The present study is a multi-center, single-arm, open, phase I/IIa clinical trial to evaluate the efficacy and safety of EBViNT Cell when administered to patients with Epstein-Barr (EBV) positive malignancies The present study…
- Trial name
- NCT03789617
- Testing
- EBViNT Cell
- Where
- 8 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Eutilex
Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC)
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
This is a multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of B1962 in the treatment of ad-vanced solid tumors.
- Conditions
- Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer
- Trial name
- NCT06724263
- Testing
- B1962
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Ototoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
RATIONALE: New ways to find out about hearing loss after treatment with chemotherapy may improve the ability to plan cancer treatment and may help patients live more comfortably.
- Trial name
- NCT00458887
- Testing
- management of therapy complications
- Where
- 81 sites in United States, Australia and 1 more
- Volunteers
- 301 people
- Sponsor
- Children's Oncology Group
Neoplasm Metastasis
A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)
The purpose of this study is to evaluate the safety, tolerability, and efficacy in participants with advanced/metastatic or recurrent malignancies who receive gebasaxturev (V937) in combination with pembrolizumab (MK-3475).
- Trial name
- NCT04521621
- Testing
- Gebasaxturev, Pembrolizumab
- Where
- 29 sites in United States, Canada and 12 more
- Volunteers
- 76 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Neoplasm
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
The purpose of this study is to assess the effect of multiple-dose administration of rifampin on the single dose PK of pevonedistat in adult participants with advanced solid tumors.
- Trial name
- NCT03486314
- Testing
- Pevonedistat, Rifampin, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Cancer, Ovarian Cancer
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
- Conditions
- Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT03667716
- Testing
- COM701, COM701 with Opdivo (Nivolumab).
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- Compugen Ltd
Colorectal Cancer
Phase I/II Study of SOL for Untreated Metastatic Colorectal Cancer
Introduction: S-1 is promising drug which could replace 5-fluorouracil plus l-leucovorin (5-FU/l-LV) in treatment of advanced colorectal cancer.
- Trial name
- NCT00524706
- Testing
- S-1, oral Leucovorin, Oxaliplatin
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Shizuoka Cancer Center
Solid Tumor Cancer, Lymphoma
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
SB-485232 will be administered as five daily intravenous (IV) infusions repeated every 28 days in adult subjects with advanced solid tumors or lymphomas.
- Trial name
- NCT00085904
- Testing
- SB-485232
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Cancer, Neoplasms
A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies
The purpose of the study is to test the safety of an experimental drug called OSI-906 when combined with pemetrexed at different dose levels and to find out the optimal doses of the two drugs that can be given as a combination.
- Conditions
- Cancer, Neoplasms, Tumors
- Trial name
- NCT01567384
- Testing
- OSI-906 and Pemetrexed
- Where
- United States
- Sponsor
- Emory University
Advanced Solid Tumors
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Objectives:To evaluate the safety and tolerability of BAT8008 for injection in patients with advanced solid tumors, explore the maximum tolerated dose (MTD), and provide the recommended dose for subsequent clinical trials.
- Trial name
- NCT05620017
- Testing
- BAT8008 for Injection
- Where
- 2 sites in China
- Volunteers
- 182 people
- Sponsor
- Bio-Thera Solutions
Fever, Sweating
Daptomycin in Treating Neutropenia and Fever in Patients With Cancer
RATIONALE: Antibiotics, such as daptomycin, may control neutropenia, fever, and infection in patients with cancer. PURPOSE: This phase II trial is studying how well daptomycin works in treating neutropenia and fever in patients…
- Conditions
- Fever, Sweating, Hot Flashes, Infection
- Trial name
- NCT00335478
- Testing
- Daptomycin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- OHSU Knight Cancer Institute
Melanoma, Metastatic Melanoma
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
This is a phase 1, multicenter, nonrandomized, open-label, dose escalation study. The study will be conducted in 2 stages, Dose Escalation and Dose Expansion.
- Conditions
- Melanoma, Metastatic Melanoma, Solid Tumor, Neoplasm
- Trial name
- NCT01425008
- Testing
- MLN2480
- Where
- 16 sites in United States, United Kingdom
- Volunteers
- 149 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.